Ikaria Acquisition Diversifies And Strengthens Mallinckrodt’s Hospital Care Portfolio
This article was originally published in The Pink Sheet Daily
But, with its $2.3 billion purchase price, Mallinckrodt is betting it can withstand a patent challenge to INOmax, an inhaled nitric oxide drug/device combo product, from an industrial gas company.
You may also be interested in...
In a partial buy-out by new private equity investor Madison Dearborn Partners, Ikaria is refocused on building out its critical care product portfolio, while a new R&D spin-out may take a route to the public markets. Existing investors have already done nicely through a series of dividends.
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.